Marseille (France), October3rd 2006 -- Pharmaxon, the Marseille-based emerging biopharmaceutical company specializing in the discovery and development of innovative drugs for nervous system disorders, today announced the completion of a seed financing round of over half a million euros. The funds will accelerate preclinical development of the company’s ongoing programs. A number of respected investors (Inserm Transfert Initiative, Esperante, Primaveris and CAAP Création, a subsidiary of Crédit Agricole Alpes Provence) participated in various ways in the funding round, with the first three taking an equity stake in Pharmaxon.
